

## Immuno-Oncology

# Progress in Tumor Research

**Vol. 42**

Series Editors

**Rolf A. Stahel** Zurich

**Solange Peters** Lausanne

---

# Immuno-Oncology

Volume Editors

**Olivier Michielin** Lausanne

**George Coukos** Lausanne

8 figures, 5 in color, and 11 tables, 2015

**KARGER**

Basel · Freiburg · Paris · London · New York · Chennai · New Delhi ·  
Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney

## Progress in Tumor Research

Formerly published as 'Progress in Experimental Tumor Research'

---

### Olivier Michielin, MD, PhD

Associate Professor  
Department of Oncology  
University Hospital of Lausanne (CHUV)  
Ludwig Cancer Research Center  
University of Lausanne  
Swiss Institute of Bioinformatics, Lausanne  
Rue du Bugnon 46 – BH09-733  
CASE POSTALE 5  
1011 Lausanne (Switzerland)

---

### George Coukos, MD, PhD

Professor  
Director, Department of Oncology  
University Hospital of Lausanne (CHUV)  
Director, Ludwig Cancer Research Center  
University of Lausanne  
Rue du Bugnon 46 – BH09-701  
CASE POSTALE 5  
1011 Lausanne (Switzerland)

#### Library of Congress Cataloging-in-Publication Data

Immuno-oncology / volume editors, Olivier Michielin, George Coukos.

p. ; cm. -- (Progress in tumor research, ISSN 2296-1895 ; vol. 42)

Includes bibliographical references and indexes.

ISBN 978-3-318-05589-4 (hard cover : alk. paper) -- ISBN 978-3-318-05590-0 (electronic version)

I. Michielin, Olivier, editor. II. Coukos, George, editor. III. Series:

Progress in tumor research ; v. 42. 2296-1895

[DNLM: 1. Immunotherapy--methods. 2. Neoplasms--therapy. W1 PR668T v.42

2015 / QZ 266]

RM370

615.3'7--dc23

2015028888

Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents®.

Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 2015 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)

www.karger.com

Printed in Germany on acid-free and non-aging paper (ISO 9706) by Kraft Druck, Ettlingen

ISSN 2296-1895

e-ISSN 2296-1887

ISBN 978-3-318-05589-4

e-ISBN 978-3-318-05590-0

**KARGER** 125 YEARS

# Contents

- VI Preface**  
Michielin, O.; Coukos, G. (Lausanne)
  
- 1 Immunotherapies in Early and Advanced Renal Cell Cancer**  
Kasenda, B.; Larkin, J.; Gore, M. (London)
- 11 Immunotherapy of Brain Tumors**  
Dutoit, V.; Migliorini, D.; Walker, P.R.; Dietrich, P.-Y. (Geneva)
- 22 Immunotherapy of Melanoma**  
Snyder, A.; Zamarin, D.; Wolchok, J.D. (New York, N.Y.)
- 30 Immunotherapy of Breast Cancer**  
Criscitello, C.; Curigliano, G. (Milan)
- 44 Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format**  
Diken, M.; Kreiter, S.; Kloke, B.; Sahin, U. (Mainz)
- 55 Immune Checkpoint Inhibitors**  
Haanen, J.B.A.G. (Amsterdam); Robert, C. (Villejuif)
- 67 Radiotherapy and Immunotherapy: Improving Cancer Treatment through Synergy**  
Reynders, K.; De Ruyscher, D. (Leuven)
- 79 Combinations Therapies**  
Reinmuth, N.; Reck, M. (Heidelberg)
- 95 Promise of Immunotherapy in Lung Cancer**  
Shanker, A. (Nashville, Tenn.); Dikov, M.M.; Carbone, D.P. (Columbus, Ohio)
- 110 T Cell Engineering**  
Pircher, M. (Zurich); Schirmann, T. (Braunschweig); Petrusch, U. (Zurich)
  
- 136 Author Index**
- 137 Subject Index**

## Preface

Over the last decade, immuno-oncology has witnessed an astonishing pace of discovery and innovation translating into unprecedented successes in the clinical setting, arguably representing one of the most profound and transforming revolution in the history of cancer therapy. A key aspect of this growing success is the path that led us there. Rather than empirical, rationally designed and molecularly defined clinical interventions from sound basic, translational and clinical research, paved the way up to drug registration. This rational approach holds the promise of further new exciting breakthroughs originating from ongoing research and discoveries that have not yet reached the clinic.

In this book, we will provide a concise, yet very accurate outline of the main developments in major tumor types including melanoma, lung, breast, brain and renal cell cancers. In addition, transversal Chapters that describe the commonalities of some of the therapeutic strategies are provided to cover topics like immune checkpoint biology, T cell engineering or rational combination therapies. Each Chapter has been authored by senior key opinion leaders in their respective fields to provide the most up-to-date view on cancer immuno-oncology. To reflect on the key translational aspect of immuno-oncology, all chapters are making explicit connections between basic science discoveries and the resulting translational therapeutic strategies.

We believe this book will be an invaluable source of information for scientists interested into the translation of basic immunology into the clinical practice, as well as for clinician interested in deepening their knowledge of current and upcoming immune strategies in the fight against cancers.

We hope the reader will share our enthusiasm for this field of research and certainly wish him an enjoyable reading!

*Olivier Michielin, Lausanne*  
*George Coukos, Lausanne*